Literature DB >> 8774479

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype.

A Marchetti1, F Buttitta, S Pellegrini, A Chella, G Bertacca, A Filardo, V Tognoni, F Ferreli, E Signorini, C A Angeletti, G Bevilacqua.   

Abstract

Bronchioloalveolar carcinoma (BAC) is a form of peripheral lung adenocarcinoma growing as a single layer of malignant cells along the walls of terminal airways. The existence of BAC as a separate clinico-pathological entity has been a matter of controversy, mainly because its histogenesis is uncertain and it is not easily distinguishable from conventional lung adenocarcinoma (CLA). Three subtypes of BAC have been described using histological and cytological criteria: mucinous, non-mucinous, and sclerosing. The clinical behaviour of BAC appears to be dependent on the histological subtype. The different morphological patterns and clinical outcome of the subtypes of BAC suggest that their biological behaviour may be different from one another and from CLA. This study has investigated 58 BACs (10 mucinous, 40 non-mucinous, and 8 sclerosing) and 50 control CLAs for mutations at codon 12 of the K-ras oncogene. Twenty-one (36 per cent) BACs and 13 (26 per cent) CLAs showed K-ras mutations. A clear association (P < 0.0001) between K-ras mutations and the mucinous type of BAC was observed: all 10 mucinous tumours examined were scored positive for mutations in the K-ras gene, while only 9 (23 per cent) of the 40 non-mucinous and 2 (25 per cent) of the 8 sclerosing BACs were found to be positive. The frequency of ras mutations in non-mucinous BAC, sclerosing BAC, and CLA was not statistically different. Our data indicate that BACs are a heterogeneous group of lung tumours and that the mucinous form might represent a biological entity separate from both the other two BAC types and CLA.

Entities:  

Mesh:

Year:  1996        PMID: 8774479     DOI: 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

1.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

2.  KRAS assay selection: sensitivity and accuracy in clinical application.

Authors:  Marta Herreros-Villanueva; Gaurav Aggarwal
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

3.  Pros: the present classification of mucinous adenocarcinomas of the lung.

Authors:  Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 4.  Do all lung adenocarcinomas follow a stepwise progression?

Authors:  Yasushi Yatabe; Alain C Borczuk; Charles A Powell
Journal:  Lung Cancer       Date:  2011-06-25       Impact factor: 5.705

5.  KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Camelia S Sima; Maria E Arcila; Cyrus Hedvat; Mark G Kris; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

6.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Liying Yan; Mami Cantor; Chungdak Namgyal; Mari Mino-Kenudson; Gregory Y Lauwers; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

Review 7.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

8.  Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia.

Authors:  Hanako Sato; Takuya Yazawa; Takehisa Suzuki; Hiroaki Shimoyamada; Koji Okudela; Masaichi Ikeda; Kenji Hamada; Hisafumi Yamada-Okabe; Masayuki Yao; Yoshinobu Kubota; Takashi Takahashi; Hiroshi Kamma; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

9.  Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.

Authors:  Erik Thunnissen; Evan Boers; Daniëlle A M Heideman; Katrien Grünberg; Dirk J Kuik; Arnold Noorduin; Matthijs van Oosterhout; Divera Pronk; Cees Seldenrijk; Hannie Sietsma; Egbert F Smit; Robertjan van Suylen; Jan von der Thusen; Bart Vrugt; Anne Wiersma; Birgit I Witte; Michael den Bakker
Journal:  Virchows Arch       Date:  2012-10-12       Impact factor: 4.064

10.  Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.

Authors:  Taro Ohba; Gouji Toyokawa; Takuro Kometani; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Motoharu Hamatake; Takashi Seto; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2013-04-23       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.